Talis Biomedical Corporation Statistics
Share Statistics
Talis Biomedical Corporation has 1.82M shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 1.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 765.11K |
| Failed to Deliver (FTD) Shares | 312 |
| FTD / Avg. Volume | 5.09% |
Short Selling Information
The latest short interest is 17.96K, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 17.96K |
| Short % of Shares Out | 0.99% |
| Short % of Float | 2.35% |
| Short Ratio (days to cover) | 0.59 |
Valuation Ratios
The PE ratio is -0.22 and the forward PE ratio is -0.08.
| PE Ratio | -0.22 |
| Forward PE | -0.08 |
| PS Ratio | 32.87 |
| Forward PS | 0.2 |
| PB Ratio | 0.2 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | n/a |
Enterprise Valuation
Talis Biomedical Corporation has an Enterprise Value (EV) of -43.52M.
| EV / Earnings | 0.7 |
| EV / Sales | -105.64 |
| EV / EBITDA | 0.66 |
| EV / EBIT | 0.65 |
| EV / FCF | 0.81 |
Financial Position
The company has a current ratio of 8.86, with a Debt / Equity ratio of 0.04.
| Current Ratio | 8.86 |
| Quick Ratio | 8.86 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 4 |
| Cash Flow / Debt | -18.47 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -75.26%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.65% |
| Return on Capital (ROIC) | -75.26% |
| Revenue Per Employee | 4.16K |
| Profits Per Employee | -626.33K |
| Employee Count | 99 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -78.76% in the last 52 weeks. The beta is 1.56, so Talis Biomedical Corporation's price volatility has been higher than the market average.
| Beta | 1.56 |
| 52-Week Price Change | -78.76% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 5.84 |
| Relative Strength Index (RSI) | 52.59 |
| Average Volume (20 Days) | 6.13K |
Income Statement
In the last 12 months, Talis Biomedical Corporation had revenue of $412.00K and earned -$62.01M in profits. Earnings per share was $-34.12.
| Revenue | 412.00K |
| Gross Profit | 371.00K |
| Operating Income | -66.81M |
| Net Income | -62.01M |
| EBITDA | -66.05M |
| EBIT | -66.81M |
| Earnings Per Share (EPS) | -34.12 |
Balance Sheet
The company has $76.73M in cash and $19.67M in debt, giving a net cash position of $57.06M.
| Cash & Cash Equivalents | 76.73M |
| Total Debt | 19.67M |
| Net Cash | 57.06M |
| Retained Earnings | -539.96M |
| Total Assets | 72.70M |
| Working Capital | 55.41M |
Cash Flow
In the last 12 months, operating cash flow was -$53.24M and capital expenditures -$486.00K, giving a free cash flow of -$53.73M.
| Operating Cash Flow | -53.24M |
| Capital Expenditures | -486.00K |
| Free Cash Flow | -53.73M |
| FCF Per Share | -29.56 |
Margins
Gross margin is 90.05%, with operating and profit margins of -16.22K% and -15.05K%.
| Gross Margin | 90.05% |
| Operating Margin | -16.22K% |
| Pretax Margin | -15.05K% |
| Profit Margin | -15.05K% |
| EBITDA Margin | -16.03K% |
| EBIT Margin | -16.22K% |
| FCF Margin | -13.04K% |
Dividends & Yields
TLIS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1995.32% |
| FCF Yield | -1723.63% |
Analyst Forecast
Currently there are no analyst rating for TLIS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Jul 6, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Jul 6, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.33 |
| Piotroski F-Score | 1 |